Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Axitinib
Related studies linked through entity extraction aliases.
Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)
- Status
- COMPLETED
- Phase
- N/A
An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK
- Status
- COMPLETED
- Phase
- N/A
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
- Status
- RECRUITING
- Phase
- PHASE2
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Status
- RECRUITING
- Phase
- PHASE2
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Avelumab, Palbociclib and Axitinib in Advanced RCC
- Status
- WITHDRAWN
- Phase
- PHASE2
StrataPATHâ„¢ (Precision Indications for Approved Therapies)
- Status
- TERMINATED
- Phase
- PHASE2
Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis
- Status
- UNKNOWN
- Phase
- PHASE1
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
- Status
- COMPLETED
- Phase
- PHASE1
Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
- Status
- COMPLETED
- Phase
- N/A
Axitinib + Ipilimumab in Advanced Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- Status
- RECRUITING
- Phase
- PHASE1
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- N/A